One of the success stories for multinational drug makers in China, AstraZeneca PLC is making inroads across multiple areas in a vast market, with a product portfolio ranging from oncology to cardiovascular to respiratory drugs. Given the right product mix and heavy local investment, the UK-based firm seems poised to take on whatever comes in the country.
During the second quarter, however, AstraZeneca’s large-selling respiratory product was impacted by decreasing demand due to the coronavirus pandemic
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?